Now, to be clear, biotech investing is notoriously risky, as it can cost hundreds of millions of dollars and years to develop a product that ultimately may not pass FDA approval. But with TradeSmith’s tools and proprietary algorithms, we’re able to help our readers go past the news and measure what ultimately matters.
Read nowImagine how much money could be made by investing in companies that could provide lifelong cures to genetic conditions. With this company, you may not have to imagine.
Read nowIn February, LikeFolio began covering 13 new companies, and while we can’t go over each and every one, there are two in particular that we want to share: Dine Brands Global (INC) and La-Z-Boy Inc. (LZB).
Read nowAs I was talking with Quantum Edge Pro Editor Jason Bodner about all this, he assured me that there was no need to suffer from information overload, as he believes just one data point should be focused on the most.
Read nowHere’s where to invest now…
Read now: Is this a crisis - or an opportunity? Hear from three experts in today's TradeSmith Daily…
Read nowSo far, stock chatter hinted which banks would fail. These two could be next...
Read nowTo make things simple, we can look within the iShares U.S. Regional Banks ETF (IAT), which will give us a list of 37 regional bank stocks to analyze with our proprietary investing tools to see what potential winners are hiding within its holdings.
Read now
